Dr. Subrata Chakrabarti Highlights RNA Therapeutics for Diabetic Retinopathy at ADA 2026; Presentation Now Available on VuMedi

i-RNA Corporation is pleased to share that Dr. Subrata Chakrabarti's presentation from the 86th Scientific Sessions of the American Diabetes Association (ADA) is now available on VuMedi, enabling healthcare professionals and researchers worldwide to access the latest preclinical findings supporting the company's HOTAIR-targeted siRNA therapeutic approach for diabetic retinopathy.

Dr. Chakrabarti's presentation, "Long Coding RNA: Novel Therapeutic Target(s) in Diabetic Retinopathy," explored the emerging role of long non-coding RNAs (lncRNAs) as novel therapeutic targets for diabetic retinopathy. Building on decades of research, he discussed how detailed analyses of lncRNAs in the diabetic retina led to the identification of HOTAIR as a novel therapeutic target, and reviewed preclinical efficacy and safety data supporting i-RNA's development of a HOTAIR-targeted siRNA eye drop as a novel, non-invasive therapeutic strategy for diabetic retinopathy.

Ahead of the conference, Dr. Chakrabarti was also featured in ADA Meeting News, where he discussed the scientific rationale behind targeting HOTAIR and the potential of RNA therapeutics to transform the treatment landscape for diabetic retinopathy.

Now available on VuMedi under the title "Managing Diabetic Retinopathy With HOTAIR-Targeted siRNA Eye Drops: Preclinical Efficacy and Safety Findings," the recording extends access to the presentation beyond the conference, supporting continued scientific exchange within the global ophthalmology and diabetes communities.

Making this presentation available on VuMedi reflects i-RNA's ongoing commitment to advancing innovative RNA therapeutics for retinal diseases and promoting the dissemination of emerging scientific research.

About i-RNA

i-RNA Corporation is a Canadian preclinical biotechnology company developing innovative siRNA therapeutics for retinal diseases. Its proprietary RNA therapeutics platform targets disease-driving pathways regulated by long non-coding RNAs (lncRNAs), with an initial focus on diabetic retinopathy, a leading cause of blindness worldwide. The company's lead program, a HOTAIR-targeted siRNA eye drop, has demonstrated robust preclinical efficacy and safety and is being developed as a novel, non-invasive therapeutic approach for diabetic retinopathy.